Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness

About this update from Agenus Inc.

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1694,"height":353,"url":"https://media.zenfs.com/en/business-wire.com/be74061dcbf9ef875bcadd963131df8e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Ti5DzgTYaCgvhQMzcvWVqg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTIwMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/be74061dcbf9ef875bcadd963131df8e","width":960,"height":200},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/VfiWfF2yPTYNa62vJ6YylQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD01MDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/be74061dcbf9ef875bcadd963131df8e","width":1200,"height":250}},"lazy":false},{"type":"text","content":"LEXINGTON, Mass., January 15, 2026--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the closing of its previously disclosed strategic collaboration with Zydus Lifesciences Ltd. The agreement is designed to accelerate global development and potential commercialization of Agenus’ botensilimab and balstilimab (BOT+BAL) immunotherapy combination program.","length":405,"tagName":"p"},{"type":"text","content":"The collaboration provides Agenus with strategic capital and committed, long-term biologics manufacturing capacity in the United States to support BOT+BAL clinical development, authorized early access pathways, and commercial supply preparation.","length":245,"tagName":"p"},{"type":"text","content":"As part of the collaboration, Agenus has granted Zydus exclusive rights to develop and commercialize BOT and BAL in India and Sri Lanka, with Agenus eligible to receive royalties on net sales in those territories.","length":213,"tagName":"p"},{"type":"text","content":"The collaboration, first announced on June 3, 2025, included the following key financial terms:","length":95,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Upfront Consideration: $75 million cash payment to Agenus for transfer of biologics manufacturing facilities in Emeryville and Berkeley, California","length":147,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Equity Investment: $16 million purchase by Zydus of Agenus (AGEN) common stock (~2.1 million shares at $7.50 per share)","length":119,"tagName":"p","attribs":{}}]},{"val":[{"type":"text",...

More updates from Agenus Inc.